|
Worldwide
Directory of Oncologists / Hematologists
knowledge
is the most powerful healing
tool
|
|
World
Oncology Network ( WON)
is a worldwide network of
communications among physicians
and nurses practicing
Hematology/Oncology.
WON is a nonprofit
organization with more than 2000
members from over 80 countries.
Includes not only those
professionals working in major
cities, centers and universities
but also those located in most
distant areas with limited
resources.
WON mails to all its
members, each time is printed, a
Directory listing names,
addresses, telephone numbers, fax
numbers and E-mails of
participant health care
providers.
Membership and participation is
and always will be FREE.
If most of your practice is
Oncology, Hematology or any of
the related specialties,
membership and your inclusion in
the WON directory is
FREE. Simply fill out
our Application
and
you will be automatically
registered for the next edition
of the WON directory.
( We pledge strict
confidentiality and all
information provided is not
shared,sold or lend under any
circumstances. See our
Privacy
Policy
)
Dr.
Ettore Piroso, MD. FACP
Director of World Oncology
Network
Minnesota,
USA
|
|
|
|
BookStore
|
|
Health
Professionals:
Browse hematology/oncology books organized
by oncology subspecialties,tumor sites or
diagnosis.
Patients
and
Public:
Books
on cancer and nutrition,alternative
treatments, side effects, chemotherapy,
natural healing,etc.
|
|
Healthcare
Professionals Resource
Center
|
|
Over
400,000 pieces of content with almost 1200
new features every month!
|
|
Career
Center
|
Physicians,
Nurses, Health Care Providers, Pharmacy
Industry
and more
Job
Seekers:
Post Anonymous Resumes
View Jobs, Set Personal Job
Alerts,etc.
Employers:
View
Resumes, Create Employer
Account,etc.
|
|
|
Oncology
Around The World
|
Experimental
Cancer Treatments
|
|
Molecular
epidemiology of human liver cancer:
insights into etiology, pathogenesis and
prevention from The Gambia, West
Africa
Human
liver cancer, primarily hepatocellular
carcinoma (HCC), is both common and
lethal. Notable variation in HCC incidence
rates worldwide corresponds to the
prevalence and pattern of the primary
etiologic factors. In summary of decades
of collaborative research centered in The
Gambia, West Africa, this review explores
the independent.
....
See
Full Article
|
|
|
Effective
Inhibition of Experimental Human Ovarian
Cancers with a Targeted Cytotoxic Bombesin
Analogue AN-215
To
determine whether the cytotoxic analogue
of bombesin/gastrin-releasing peptide
(GRP) AN-215 can inhibit the in vivo
growth of four human ovarian cancer cell
lines. AN-215 consists of
2-pyrrolinodoxorubicin (AN-201), a
superactive derivative of doxorubicin
linked to a bombesin antagonist carrier
des-D-Tpi-RC-3095. This conjugate binds
strongly to receptors for bombesin/GRP
....
See
Full Article
|
|
|
|
|
|
CANCER
ECONOMICS
|
PALLIATIVE
CARE
|
|
Creating
Standard Cost Measures Across Integrated
Health Care Delivery Systems
Economic
analyses are increasingly important in
medical research. Accuracy often requires
that they include large, diverse
populations, which requires data from
multiple sources. The difficulty is in
making the data comparable across
different settings. This article
focuses....
See
Full Article
|
|
|
|
Palliative
Care: Optimizing Quality of Life
Many
developments have occurred in the prevention and
treatment of cancer, but death from this disease is
still common. According to the World Health
Organization, 7 million deaths were due to cancer
worldwide in 1999. For dying patients, it is most
important to improve quality of life and relieve
suffering. Palliative care is defined as the active
total care of patients whose disease is not
responsive to curative treatment. It encompasses
all treatment modalities that are aimed at
enhancing quality of life rather than ..
See
Full Article
|
|
The
molecular pathogenesis of pancreatic
cancer: clarifying a complex
circuitry
The
preponderance of pancreatic malignancies
is constituted by pancreatic ductal
adenocarcinomas, abbreviated as either PDA
or PDAC in the literature and used
interchangeably with the generic term
pancreatic cancer. Other types of
pancreatic malignancies, albeit uncommon
and not meant to be exhaustive, include
neuroendocrine tumors, acinar cell
carcinomas, lymphomas, sarcomas, serous
cystadenocarcinoma, and pancreatoblastoma,
among other rare entities (Hruban 2006).
PDAC is a disease that has a number of
clinical challenges. There are 33,000 new
cases that occur annually in the United
States, with nearly the same number of
deaths predominantly related to metastatic
....
See
Full
Article
|
|
|
LEGAL
ISSUES IN CANCER
|
ETHICS
AND CANCER CARE
|
|
The
Attorney As the Newest Member of the
Cancer Treatment Team
In
a recent survey of cancer patients
conducted by the Lance Armstrong
Foundation (Austin, TX), nearly half of
the individuals surveyed said that
nonmedical issues relating to their cancer
were unmet by their oncologists, including
35% who said nonmedical issues were wholly
unaddressed and another 14% who said they
believed their oncologists wanted to
assist with nonmedical issues but did
not...
See
Full Article
|
|
|
Do
oncologists discuss expensive anti-cancer
drugs with their patients?
Patients
generally wish to receive as much
information as possible, particularly in
relation to treatment options, and wish to
be active participants in treatment
decision-making , yet cannot make informed
decisions unless they are presented with
all relevant information. Shared
decision-making is considered the best
practice approach to negotiating treatment
plans [5], both according to
professional ....
See
Full Article
|
|
|
Search
ClinicalTrials.Gov
|
|
|
|
|
|